Literature DB >> 32056227

Fecal Microbiome Distinguishes Alcohol Consumption From Alcoholic Hepatitis But Does Not Discriminate Disease Severity.

Ekaterina Smirnova1, Puneet Puri2, Mark D Muthiah3,4, Kalyani Daitya2, Robert Brown5, Naga Chalasani6, Suthat Liangpunsakul6, Vijay H Shah7, Kayla Gelow8, Mohammed S Siddiqui2, Sherry Boyett2, Faridoddin Mirshahi2, Masoumeh Sikaroodi5, Patrick Gillevet5, Arun J Sanyal2.   

Abstract

BACKGROUND AND AIMS: The role of the intestinal microbiome in alcoholic hepatitis is not established. The aims of this study were to (1) characterize the fecal microbial ecology associated with alcoholic hepatitis, (2) relate microbiome changes to disease severity, and (3) infer the functional relevance of shifts in microbial ecology. APPROACH AND
RESULTS: The fecal microbiome in patients with moderate alcoholic hepatitis (MAH) or severe alcoholic hepatitis (SAH) was compared with healthy controls (HCs) and heavy drinking controls (HDCs). Microbial taxa were identified by 16S pyrosequencing. Functional metagenomics was performed using PICRUSt. Fecal short chain fatty acids (SCFAs) were measured using a liquid chromatography-mass spectrometry platform. A total of 78 participants (HC, n = 24; HDC, n = 20; MAH, n = 10; SAH, n = 24) were studied. HDC had a distinct signature compared with HC with depletion of Bacteroidetes (46% vs. 26%; P = 0.01). Alcoholic hepatitis was associated with a distinct microbiome signature compared with HDC (area under the curve = 0.826); differential abundance of Ruminococcaceae, Veillonellaceae, Lachnospiraceae, Porphyromonadaceae, and Rikenellaceae families were the key contributors to these differences. The beta diversity was significantly different among the groups (permutational multivariate analysis of variance [PERMANOVA] P < 0.001). SAH was associated with increased Proteobacteria (SAH 14% vs. HDC 7% and SAH vs. HC 2%, P = 0.20 and 0.01, respectively). Firmicutes abundance declined from HDC to MAH to SAH (63% vs. 53% vs. 48%, respectively; P = 0.09, HDC vs. SAH). Microbial taxa did not distinguish between MAH and SAH (PERMANOVA P = 0.785). SCFAs producing bacteria (Lachnospiraceae and Ruminococcaceae) were decreased in alcoholic hepatitis, and a similar decrease was observed in fecal SCFAs among alcoholic hepatitis patients.
CONCLUSIONS: There are distinct changes in fecal microbiome associated with the development, but not severity, of alcoholic hepatitis.
© 2020 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2020        PMID: 32056227      PMCID: PMC7752764          DOI: 10.1002/hep.31178

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  28 in total

Review 1.  Role of short-chain fatty acids in colonic inflammation, carcinogenesis, and mucosal protection and healing.

Authors:  Christina M van der Beek; Cornelis H C Dejong; Freddy J Troost; Ad A M Masclee; Kaatje Lenaerts
Journal:  Nutr Rev       Date:  2017-04-01       Impact factor: 7.110

2.  PERFect: PERmutation Filtering test for microbiome data.

Authors:  Ekaterina Smirnova; Snehalata Huzurbazar; Farhad Jafari
Journal:  Biostatistics       Date:  2019-10-01       Impact factor: 5.899

Review 3.  Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either.

Authors:  Phillipp Hartmann; Huikuan Chu; Yi Duan; Bernd Schnabl
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-02-15       Impact factor: 4.052

Review 4.  Medical Management of Severe Alcoholic Hepatitis: Expert Review from the Clinical Practice Updates Committee of the AGA Institute.

Authors:  Mack C Mitchell; Lawrence S Friedman; Craig J McClain
Journal:  Clin Gastroenterol Hepatol       Date:  2017-01       Impact factor: 11.382

5.  Healthy donor faecal transplant for corticosteroid non-responsive severe alcoholic hepatitis.

Authors:  Cyriac Abby Philips; Nikhil Phadke; Karthik Ganesan; Philip Augustine
Journal:  BMJ Case Rep       Date:  2017-11-08

6.  Bile acid homeostasis and intestinal dysbiosis in alcoholic hepatitis.

Authors:  Dragos Ciocan; Cosmin Sebastian Voican; Laura Wrzosek; Cindy Hugot; Dominique Rainteau; Lydie Humbert; Anne-Marie Cassard; Gabriel Perlemuter
Journal:  Aliment Pharmacol Ther       Date:  2018-08-24       Impact factor: 8.171

7.  Quantitative assessment of the human gut microbiome using multitag pyrosequencing.

Authors:  Patrick Gillevet; Masoumeh Sikaroodi; Ali Keshavarzian; Ece A Mutlu
Journal:  Chem Biodivers       Date:  2010-05       Impact factor: 2.408

8.  Reprogramming of hepatic fat accumulation and 'browning' of adipose tissue by the short-chain fatty acid acetate.

Authors:  M Sahuri-Arisoylu; L P Brody; J R Parkinson; H Parkes; N Navaratnam; A D Miller; E L Thomas; G Frost; J D Bell
Journal:  Int J Obes (Lond)       Date:  2016-02-12       Impact factor: 5.095

9.  Metagenomic biomarker discovery and explanation.

Authors:  Nicola Segata; Jacques Izard; Levi Waldron; Dirk Gevers; Larisa Miropolsky; Wendy S Garrett; Curtis Huttenhower
Journal:  Genome Biol       Date:  2011-06-24       Impact factor: 13.583

10.  An atlas of genetic influences on human blood metabolites.

Authors:  So-Youn Shin; Eric B Fauman; Ann-Kristin Petersen; Jan Krumsiek; Rita Santos; Jie Huang; Matthias Arnold; Idil Erte; Vincenzo Forgetta; Tsun-Po Yang; Klaudia Walter; Cristina Menni; Lu Chen; Louella Vasquez; Ana M Valdes; Craig L Hyde; Vicky Wang; Daniel Ziemek; Phoebe Roberts; Li Xi; Elin Grundberg; Melanie Waldenberger; J Brent Richards; Robert P Mohney; Michael V Milburn; Sally L John; Jeff Trimmer; Fabian J Theis; John P Overington; Karsten Suhre; M Julia Brosnan; Christian Gieger; Gabi Kastenmüller; Tim D Spector; Nicole Soranzo
Journal:  Nat Genet       Date:  2014-05-11       Impact factor: 38.330

View more
  29 in total

1.  Demonstration of Gut-Barrier Dysfunction in Early Stages of Non-alcoholic Fatty Liver Disease: A Proof-Of-Concept Study.

Authors:  Kanav Kaushal; Samagra Agarwal; Sanchit Sharma; Pooja Goswami; Namrata Singh; Vikas Sachdev; Shekhar Poudel; Prasenjit Das; Rajni Yadav; Dinesh Kumar; Gaurav Pandey; Deepak Gunjan; Anoop Saraya
Journal:  J Clin Exp Hepatol       Date:  2022-01-24

Review 2.  Current Medical Treatment for Alcohol-Associated Liver Disease.

Authors:  Gustavo Ayares; Francisco Idalsoaga; Luis A Díaz; Jorge Arnold; Juan P Arab
Journal:  J Clin Exp Hepatol       Date:  2022-02-12

Review 3.  The Beneficial Effects of Natural Extracts and Bioactive Compounds on the Gut-Liver Axis: A Promising Intervention for Alcoholic Liver Disease.

Authors:  Liang Zhao; Shaoxuan Wang; Nanhai Zhang; Jingxuan Zhou; Arshad Mehmood; Rifat Nowshin Raka; Feng Zhou; Lei Zhao
Journal:  Antioxidants (Basel)       Date:  2022-06-20

Review 4.  Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future.

Authors:  Sonja Lang; Bernd Schnabl
Journal:  Cell Host Microbe       Date:  2020-08-12       Impact factor: 21.023

Review 5.  Interleukin-22 in alcoholic hepatitis and beyond.

Authors:  Xiaogang Xiang; Seonghwan Hwang; Dechun Feng; Vijay H Shah; Bin Gao
Journal:  Hepatol Int       Date:  2020-09-05       Impact factor: 6.047

Review 6.  Gut microbiome, liver immunology, and liver diseases.

Authors:  Rui Wang; Ruqi Tang; Bo Li; Xiong Ma; Bernd Schnabl; Herbert Tilg
Journal:  Cell Mol Immunol       Date:  2020-12-14       Impact factor: 11.530

Review 7.  Microbiota reprogramming for treatment of alcohol-related liver disease.

Authors:  Mohamed Tausif Siddiqui; Gail A M Cresci
Journal:  Transl Res       Date:  2020-07-17       Impact factor: 7.012

Review 8.  Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease.

Authors:  Chathur Acharya; Jasmohan S Bajaj
Journal:  Gastroenterology       Date:  2020-11-28       Impact factor: 33.883

Review 9.  Malnutrition and Alcohol-Associated Hepatitis.

Authors:  Craig J McClain; Cristian D Rios; Sally Condon; Luis S Marsano
Journal:  Clin Liver Dis       Date:  2021-05-26       Impact factor: 6.126

10.  New strain of Pediococcus pentosaceus alleviates ethanol-induced liver injury by modulating the gut microbiota and short-chain fatty acid metabolism.

Authors:  Xian-Wan Jiang; Ya-Ting Li; Jian-Zhong Ye; Long-Xian Lv; Li-Ya Yang; Xiao-Yuan Bian; Wen-Rui Wu; Jing-Jing Wu; Ding Shi; Qing Wang; Dai-Qiong Fang; Kai-Cen Wang; Qiang-Qiang Wang; Yan-Meng Lu; Jiao-Jiao Xie; Lan-Juan Li
Journal:  World J Gastroenterol       Date:  2020-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.